An index to identify stroke-related vs incidental patent foramen ovale in cryp- togenic stroke. Neurology. 2013;81:619 625. doi: 10.1212/WNL. 567. Kuijpers T, Spencer FA, Siemieniuk RAC, Vandvik PO, Otto CM, Lytvyn L, Mir H, Jin AY, Manja V, Karthikeyan G, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ. 2018;362:k2515. 568. Kent DM, Saver JL, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Smalling RW, J ni P, Mattle HP, Meier B, et al. Risk of Paradoxical Embolism (RoPE)- estimated attributable fraction correlates with the benefit of patent fora- men ovale closure: an analysis of 3 trials. Stroke. 2020;51:3119 3123. 569. Mazzucco S, Li L, Rothwell PM. Prognosis of cryptogenic stroke with pat- ent foramen ovale at older ages and implications for trials: a population- based study and systematic review. JAMA Neurol. 2020;77:1 9. doi: 570. Deng W, Yin S, McMullin D, Inglessis-Azuaje I, Elmariah S, Hung J, Lo EH, Palacios IF, Buonanno FS, Ning M. Residual shunt after patent fo- ramen ovale closure and long-term stroke recurrence. Ann Intern Med. 571. Mess SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, Carroll JD, Ishida K, Sangha N, Kasner SE. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. 572. Seipelt RG, Franke A, Vazquez-Jimenez JF, Hanrath P, von Bernuth G, Messmer BJ, M hler EG. Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches. Ann Thorac 573. Monagle P, Cochrane A, Roberts R, Manlhiot C, Weintraub R, Szechtman B, Hughes M, Andrew M, McCrindle BW; Fontan Anticoagulation Study Group. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. 